Navigation Links
Astellas Adds CNS Therapy Area Leader to Global R&D Team
Date:6/4/2009

DEERFIELD, Ill., June 4 /PRNewswire/ -- Astellas Pharma Global Development ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Betsy Garofalo has been hired as the global therapy area leader for CNS. Garofalo is a pediatric neurologist and epileptologist bringing the team more than 17 years of drug development experience.

"Betsy's charge as head of the global therapy area is to provide strategic direction and leadership for the development of all Astellas CNS compounds," said Dr. Steven Ryder, president of APGD. "Betsy's deep experience in CNS disorders and past successes make her an excellent choice to help us develop new medications for the many patients with unmet medical needs."

In addition to her work at Astellas, Garofalo is an adjunct associate professor of pediatrics at the University of Michigan. In 2007, Garofalo formed the Michigan Technology and Research Institute where she provided consulting services to the pharmaceutical industry. Before that, Garofalo held numerous positions of leadership at Parke-Davis and then Pfizer Research and Development. She received her medical training and completed a pediatric residency at the Indiana University School of Medicine followed by a fellowship in neurology/pediatric neurology and a fellowship in epilepsy at the University of Michigan.

About Astellas

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma Inc., please visit the website at www.astellas.com/en/.


'/>"/>
SOURCE Astellas Pharma Global Development
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Hires New Vice President of Compliance
2. Astellas Announces New Vice President of Marketing
3. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
4. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
5. FDA Approves Additional Indication for Astellas MYCAMINE(R)
6. Cardiome And Astellas Announce Regulatory Update
7. Pausing Hormone Therapy Doesnt Cut Mammogram Recalls
8. Oxygen + MRI might help determine cancer therapy success, researchers find
9. QLT announces positive results from the evaluation of Visudyne(R) combination therapy
10. New Journal of Natural Medicine Launched This June, Promotes Natural Therapy
11. New Data Support Use of Simple Test to Predict Endometrial Cancer Response to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
Breaking Medicine Technology: